Results 51 to 60 of about 337 (145)

Limitations of PLX3397 as a microglial investigational tool: peripheral and off-target effects dictate the response to inflammation

Frontiers in Immunology, 2023
Microglia, the resident macrophages of the central nervous system (CNS), play a critical role in CNS homeostasis and neuroinflammation. Pexidartinib (PLX3397), a colony-stimulating factor 1 (CSF1) receptor inhibitor, is widely used to deplete microglia ...
Wouter Claeys, Wouter Claeys, Wouter Claeys, Wouter Claeys, Daan Verhaege, Daan Verhaege, Griet Van Imschoot, Griet Van Imschoot, Elien Van Wonterghem, Elien Van Wonterghem, Lore Van Acker, Lore Van Acker, Laura Amelinck, Laura Amelinck, Federico F. De Ponti, Federico F. De Ponti, Charlotte Scott, Charlotte Scott, Anja Geerts, Anja Geerts, Anja Geerts, Christophe Van Steenkiste, Christophe Van Steenkiste, Lien Van Hoecke, Lien Van Hoecke, Roosmarijn E. Vandenbroucke, Roosmarijn E. Vandenbroucke   +26 more
doaj   +1 more source

Perianesthetic Complications in Genetic Mitochondrial Disease: A Review of Case Reports

Pediatric Anesthesia, Volume 36, Issue 10, Page 1217-1230, October 2026.
ABSTRACT Background Genetic mitochondrial diseases (GMDs) are a large group of genetically and clinically heterogeneous disorders caused by defects in genes encoding mitochondrial components. GMDs are grouped into named syndromes based on clinical presentation, for example, Leigh syndrome (LS).
Brittany M. Johnson, Simon C. Johnson
wiley   +1 more source

Adverse events of pexidartinib for the treatment of TGCT: a real-world disproportionality analysis using FDA Adverse Event Reporting System database

Frontiers in Oncology
IntroductionPexidartinib, an oral selective colony-stimulating factor 1 receptor (CSF1R) inhibitor, is the only systemic therapy approved by the U.S. Food and Drug Administration (FDA) for tenosynovial giant cell tumor (TGCT).
Yu Lin, Xinlei Zheng, Li Lin, Maohua Chen   +3 more
doaj   +1 more source

Vimseltinib for patients with tenosynovial giant cell tumor: A multicenter, open‐label, phase 2 trial

Cancer, Volume 132, Issue 17, 1 September 2026.
Abstract Background Tenosynovial giant cell tumor (TGCT) is a locally aggressive neoplasm caused by dysregulation of the colony‐stimulating factor 1 (CSF1) gene. Patients report substantial pain, stiffness, and declining physical function; those whose disease is not amenable to surgery require systemic therapy.
Silvia Stacchiotti, Jean‐Yves Blay, Piotr Rutkowski, Hans Gelderblom, Alejandro Falcón, Axel Le Cesne, Jayesh Desai, Emanuela Palmerini, César Serrano, Kristen N. Ganjoo, Gina Z. D’Amato, Christopher W. Ryan, Breelyn A. Wilky, Virginia Ferraresi, Ramy Saleh, Vinod Ravi, Albiruni Abdul Razak, Antonio Casado Herráez, Mahbubl Ahmed, Nicholas M. Bernthal, Michiel van de Sande, Mehdi Brahmi, Bartlomiej Szostakowski, Jasmine Sen, Nicholas A. Zeringo, Brooke Harrow, Supraja Narasimhan, Amanda Saunders, Maitreyi G. Sharma, Matthew L. Sherman, Andrew J. Wagner, William D. Tap   +31 more
wiley   +1 more source

Patient-Reported Continued Benefits in Patients Treated with Pexidartinib for Tenosynovial Giant Cell Tumor Based on a Real-World Study in the United States

Foot & Ankle Orthopaedics
Category: Other Introduction/Purpose: Tenosynovial giant cell tumors (TGCT) are neoplastic, inflammatory lesions that arise within the synovium and can be locally aggressive.
Margaret Wooddell PhD, MBA, Dong Dai PhD, Feng Lin PhD, Irene Pan MS, Klaus Freivogel PhD, Xin Ye PhD, Kristen Tecson PhD, William D. Tap MD   +7 more
doaj   +1 more source

Pexidartinib, a Novel Small Molecule CSF-1R Inhibitor in Use for Tenosynovial Giant Cell Tumor: A Systematic Review of Pre-Clinical and Clinical Development

Drug Design, Development and Therapy, 2020
Brooke Benner,1,* Logan Good,1,* Dionisia Quiroga,2 Thomas E Schultz,3 Mahmoud Kassem,2 William E Carson,1 Mathew A Cherian,2 Sagar Sardesai,2 Robert Wesolowski2 1Department of Surgery, The Ohio State University Comprehensive Cancer Center, Columbus, OH,
Benner B, Good L, Quiroga D, Schultz TE, Kassem M, Carson WE, Cherian MA, Sardesai S, Wesolowski R   +8 more
doaj  

What’s new in musculoskeletal oncology

BMC Musculoskeletal Disorders, 2021
We reviewed the recent literature related to primary musculoskeletal tumors and metastatic bone tumors. With regard to primary bone tumors, computer navigation systems and three-dimensional-printed prostheses seem to be new treatment options, especially ...
Costantino Errani, Andreas F. Mavrogenis, Shinji Tsukamoto   +2 more
doaj   +1 more source

Microglia‐Mediated Neuroimmune Response Regulates Cardiac Remodeling After Myocardial Infarction

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2023
Background Sympathetic hyperactivity contributes to pathological remodeling after myocardial infarction (MI). However, the mechanisms underlying the increase in sympathetic activity remain unknown.
Menglong Wang, Jishou Zhang, Zheng Yin, Wen Ding, Mengmeng Zhao, Jianfang Liu, Yao Xu, Shuwan Xu, Wei Pan, Cheng Wei, Hong Jiang, Jun Wan   +11 more
doaj   +1 more source

Tissue‐Resident Macrophage in Inflammation and Cancer

MedComm, Volume 7, Issue 9, September 2026.
Opposing macrophage functions in inflammation and cancer converge on shared mechanistic nodes, informing cross‐disease therapeutic strategies. ABSTRACT Tissue‐resident macrophages (TRMs) are long‐lived immune cells strategically distributed across organs, where their functional plasticity enables both homeostatic maintenance and pathological ...
Siyuan Huang, Jiangbo Fan, Wenyi Liu, Di Liu, Rui Wang, Yuanyang Wang, Jianhui Sun, Huacai Zhang, Qingli Cai, Zhe Xu, Fang Xu, Jianxin Jiang, Zhen Wang, Ling Zeng   +13 more
wiley   +1 more source

ENLIVEN study: Pexidartinib for tenosynovial giant cell tumor (TGCT)

Future Oncology, 2020
Pexidartinib is the first approved medication in the USA for people with tenosynovial giant cell tumor (TGCT). The drug was approved based on the ENLIVEN study, which looked at pexidartinib (brand name, Turalio™), a medication taken by mouth (orally) for people with TGCT (also known as giant cell tumor of the tendon sheath [GCTTS] and pigmented ...
openaire   +2 more sources